Skip to main content
Erschienen in: International Urogynecology Journal 12/2016

01.12.2016 | Original Article

Which factors should be considered in choosing pessary type and size for pelvic organ prolapse patients in a fitting trial?

verfasst von: Jing Ding, Xiao-chen Song, Mou Deng, Lan Zhu

Erschienen in: International Urogynecology Journal | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction and hypothesis

This study explored whether the optimal pessary type and size can be predicted using the specific pelvic organ prolapse quantification system (POP-Q) measurements in women with pelvic organ prolapse in a fitting trial.

Methods

We conducted a prospective study in women who had undergone pessary fitting. A total of 78 patients with stage II, III or IV symptomatic pelvic organ prolapse completed a detailed history. Data were analysed using nonparametric tests, continuity correction chi-squared tests and multivariate logistic regression.

Results

Differences in total vaginal length (TVL; p < 0.01) and vaginal introitus width/TVL ratio (p = 0.012) were observed between patients with and without a history of hysterectomy. Patients with a history of hysterectomy and patients with a larger vaginal introitus had more success with the Gellhorn pessary than with the ring pessary with support (p = 0.005 and p = 0.01, respectively). Factors determining the size of the ring pessary with support were the genital hiatus (GH) width (p = 0.044), TVL (p = 0.011), vaginal introitus width (p < 0.001), and vaginal introitus width/TVL ratio (p = 0.025). Factors determining the size of the Gellhorn pessary were the GH width (p = 0.025), GH width/TVL ratio (p = 0.013), vaginal introitus width (p = 0.003), vaginal introitus width/TVL ratio (p = 0.001), stage of apical prolapse (p = 0.006) and stage of posterior prolapse (p = 0.003).

Conclusions

Patients with a history of hysterectomy or with a larger vaginal introitus were more likely to achieve success with the Gellhorn pessary. The GH width and the vaginal introitus width influenced the size of both pessaries chosen. The TVL was predictive of the optimal size of the ring pessary with support but was not predictive of the optimal size of the Gellhorn pessary. Finally, the size of the Gellhorn pessary was associated with POP stage.
Literatur
5.
Zurück zum Zitat Bump RC, Mattiasson A, Bo K, Brubaker LP, DeLancey JOL, Klarskov P, Shull BL, Smith AR (1996) The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 175:10–17. doi:10.1016/S0002-9378(96)70243-0 CrossRefPubMed Bump RC, Mattiasson A, Bo K, Brubaker LP, DeLancey JOL, Klarskov P, Shull BL, Smith AR (1996) The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction. Am J Obstet Gynecol 175:10–17. doi:10.​1016/​S0002-9378(96)70243-0 CrossRefPubMed
8.
Zurück zum Zitat Clemons JL, Aguilar VC, Tillinghast TA, Jackson ND, Myers DL (2014) Patient satisfaction and changes in prolapse and urinary symptoms in women who were fitted successfully with a pessary for pelvic organ prolapse. Am J Obstet Gynecol 190:1025–1029. doi:10.1016/j.ajog.2003.10.711 CrossRef Clemons JL, Aguilar VC, Tillinghast TA, Jackson ND, Myers DL (2014) Patient satisfaction and changes in prolapse and urinary symptoms in women who were fitted successfully with a pessary for pelvic organ prolapse. Am J Obstet Gynecol 190:1025–1029. doi:10.​1016/​j.​ajog.​2003.​10.​711 CrossRef
11.
Zurück zum Zitat Terry C, Mutone MF, Hale DS, Benson JT (2005) Factors which influence the short-term success of pessary management of pelvic organ prolapse. Am J Obstet Gynecol 93:89–94. doi:10.1016/j.ajog.2004.12.012 Terry C, Mutone MF, Hale DS, Benson JT (2005) Factors which influence the short-term success of pessary management of pelvic organ prolapse. Am J Obstet Gynecol 93:89–94. doi:10.​1016/​j.​ajog.​2004.​12.​012
Metadaten
Titel
Which factors should be considered in choosing pessary type and size for pelvic organ prolapse patients in a fitting trial?
verfasst von
Jing Ding
Xiao-chen Song
Mou Deng
Lan Zhu
Publikationsdatum
01.12.2016
Verlag
Springer London
Erschienen in
International Urogynecology Journal / Ausgabe 12/2016
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI
https://doi.org/10.1007/s00192-016-3051-3

Weitere Artikel der Ausgabe 12/2016

International Urogynecology Journal 12/2016 Zur Ausgabe

Urogynecology Digest

Urogynecology digest

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.